Trend and survival benefit of Oncotype DX use among female hormone receptor-positive breast cancer patients in 17 SEER registries, 2004-2015.
Trend and survival benefit of Oncotype DX use among female hormone receptor-positive breast cancer patients in 17 SEER registries, 2004-2015.
复制标题
2004-2015 年 17 个 SEER 注册中心的女性激素受体阳性乳腺癌患者使用 Oncotype DX 的趋势和生存获益。
DOI：
10.1007/s10549-020-05557-x
复制
发表时间：
2020-04
影响因子：
3.8
通讯作者：
Wu XC
中科院分区：
文献类型：
--
作者：
Zhang L;Hsieh MC;Petkov V;Yu Q;Chiu YW;Wu XC
检查（1）2004-2015年激素受体阳性（HR+）乳腺癌（BC）患者中Oncotype DX（ODX）使用的趋势和相关因素;（2）复发评分（RS）报告的化疗趋势;（3）与ODX使用相关的生存差异。ODX数据来自Genomic Health Inc.与17个SEER登记数据相关联。分析2004-2015年淋巴结阴性（N 0）或1-3个阳性淋巴结（N1）的HR + BC病例。采用Cochrane-Armitage趋势检验、Logistic回归、Kaplan-Meier生存曲线和分层考克斯模型进行分析。生存分析仅限于2010年至2014年的HR+/HER 2 −患者，倾向评分匹配。2004年至2015年，ODX使用量大幅增加（N 0：2.0%至42.7%; N1：0.3%至27.9%）。非西班牙裔黑人和医疗补助保险患者接受ODX的几率较低。中等分化或2.1-5.0 cm肿瘤的N 0例患者和高分化或< 2.0 cm肿瘤的N1例患者使用ODX的几率较高。在N 0患者中，低RS和中等RS患者报告的化疗使用显著减少，高RS患者报告的化疗使用增加。ODX使用与更好的乳腺癌特异性生存期[风险比（95% CI）N 0 1.96（1.60-2.41），N1 1.90（1.42-2.54）]和总生存期[N 0 2.06（1.83-2.31），N1 1.72（1.42-2.09）]相关，尤其是在前36个月。自2004年以来，ODX的使用显著增加，但差异仍然存在，特别是对于种族/少数民族和医疗补助保险患者。基于ODX结果的化疗在N 0患者中得到改善。接受ODX治疗的患者生存率高于未接受ODX治疗的患者。
To examine (1) the trend and associated factors of Oncotype DX (ODX) use among hormone receptor-positive (HR+) breast cancer (BC) patients in 2004–2015; (2) the trend of reported chemotherapy by Recurrence Score (RS); and (3) the survival differences associated with ODX use. ODX data from Genomic Health Inc. were linked with 17 SEER registries data. HR + BC cases with lymph node negative (N0) or 1–3 positive LNs (N1) from 2004–2015 were analyzed. The Cochrane-Armitage trend test, logistic regression, Kaplan–Meier survival curve, and stratified Cox model were performed. Survival analysis was restricted to HR+/HER2− patients from 2010 to 2014, matched on propensity score. ODX use increased substantially from 2004 to 2015 (N0: 2.0% to 42.7%; N1: 0.3% to 27.9%). Non-Hispanic black and Medicaid insured patients had lower odds of receiving ODX. N0 patients with moderately differentiated or 2.1–5.0 cm tumor and N1 patients with well-differentiated or < 2.0 cm tumor had higher odds of using ODX. The reported chemotherapy use decreased significantly with low and intermediate RS, and increased for high RS among N0 patients. ODX use was associated with better breast cancer-specific survival [hazard ratio (95% CI) N0 1.96 (1.60–2.41), N1 1.90 (1.42–2.54)] and overall survival [N0 2.06 (1.83–2.31), N1 1.72 (1.42–2.09)], especially in the first 36 months. ODX use has increased significantly since 2004, nonetheless disparities remain, especially for racial/ethnic minorities and Medicaid insured patients. Administering chemotherapy based on ODX results has been improved among N0 patients. Patients receiving ODX had better survival than those not.
登录
查看更多内容
DOI：
10.1056/nejmoa1510764
发表时间：
2015-11-19
期刊：
The New England journal of medicine
影响因子：
--
作者：
Sparano JA;Gray RJ;Makower DF;Pritchard KI;Albain KS;Hayes DF;Geyer CE Jr;Dees EC;Perez EA;Olson JA Jr;Zujewski J;Lively T;Badve SS;Saphner TJ;Wagner LI;Whelan TJ;Ellis MJ;Paik S;Wood WC;Ravdin P;Keane MM;Gomez Moreno HL;Reddy PS;Goggins TF;Mayer IA;Brufsky AM;Toppmeyer DL;Kaklamani VG;Atkins JN;Berenberg JL;Sledge GW
通讯作者：
Sledge GW
影响因子：
3.8
作者：
Enewold, Lindsey;Geiger, Ann M.;Harlan, Linda C.
通讯作者：
Harlan, Linda C.
SEER 治疗数据与医疗保险索赔的比较。
影响因子：
3
作者：
Noone AM;Lund JL;Mariotto A;Cronin K;McNeel T;Deapen D;Warren JL
通讯作者：
Warren JL
影响因子：
10.3
作者：
Kurian, Allison W.;Bondarenko, Irina;Katz, Steven J.
通讯作者：
Katz, Steven J.
影响因子：
3.8
作者：
Carlson, Josh J.;Roth, Joshua A.
通讯作者：
Roth, Joshua A.